Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Xilio Therapeutics ( (XLO) ) has shared an announcement.
Xilio Therapeutics announced significant progress in its pipeline and financial updates for Q3 2024, highlighting initial Phase 1C data for its cancer drug vilastobart in combination with atezolizumab. The company plans to release Phase 2 results by year-end, alongside data for its IL-12 therapy, XTX301. Financially, Xilio’s cash position improved to $61.3 million, projecting sufficient funds through mid-2025, as it continues to advance its innovative tumor-activated immuno-oncology therapies.
See more data about XLO stock on TipRanks’ Stock Analysis page.
